Clinical trial
DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV…
NCT00116415 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00116415 |
|---|---|
| Title | DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy |
| Official title | Daily Antiretroviral Therapy (DART 1): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Didanosine Enteric Coated (Ddl-EC) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in Anti-Retroviral Therapy (ART) Naive HIV-Infected… |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV Infections, AIDS |
| Intervention type | Drug |
| Interventions | efavirenz, didanosine EC, lamivudine |
| Enrollment | 65 |
| Start date | Mar 1, 2002 |
| Primary completion | Nov 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Jun 30, 2005 |
| Last update posted | Apr 22, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: